# US 8,278,095 B2 · Amnion-derived cell compositions, methods of making and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,095 B2
- Document ID: US8278095B2
- Status: Granted
- Kind: B2
- Application number: 12/218,655
- Filed: 2008-07-17
- Published: 2009-03-19
- Granted: 2012-10-02
- Earliest claimed: 2005-03-31
- Assignees: Stemnion, Inc.
- Inventors: Diana L. Clarke; Charlotte A. Smith; Vivienne S. Marshall
- Web page: https://patentgrep.com/patent/US8278095B2

## CPC

- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 8/982: {Reproductive organs; Embryos, Eggs}
- A61Q 19/00: Preparations for care of the skin
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0629: {Keratinocytes; Whole skin}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 2800/10: General cosmetic use
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2502/02: embryonic cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.

## Claims

### Claim 1

A substantially purified population of cultured amnion-derived epithelial cells that is made by the method comprising the steps of
a) obtaining a placenta and isolating an amnion from the placenta,
b) enzymatically releasing amnion-derived epithelial cells from the amnion,
c) collecting the released amnion-derived epithelial cells, and
d) culturing the collected amnion-derived epithelial cells of step (c) in basal culture medium that is supplemented with human serum albumin and recombinant human EGF.

### Claim 2 (depends on 1)

The population of claim 1 wherein the basal medium is IMDM.

### Claim 3 (depends on 2)

The population of claim 2 wherein the IMDM is supplemented with 0.5% human serum albumin.

### Claim 4 (depends on 1)

The population of claim 1 wherein the recombinant human EGF is at a concentration of 10 ng/mL of culture medium.

### Claim 5 (depends on 1)

The substantially purified population of claim 1 wherein the substantially purified population, the basal medium, and all medium supplements are free of xeno-contamination.

### Claim 6 (depends on 1)

The substantially purified population of claim 1 wherein the collected cells of step c) are negative for expression of the protein markers CD90, CD117 and CD105.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the substantially purified population of claim 1.

### Claim 8 (depends on 1)

The cultured amnion-derived epithelial cells of claim 1 which are further processed by the step of (e) expanding the cells to a ratio of at least 500×106 amnion-derived epithelial cells/g of starting amnion.

### Claim 9 (depends on 6)

The substantially purified population of claim 6, wherein the collected cells in step c) are further negative for telomerase expression.
